Biotechnology Assets Valuation
| BST Stock | 0.34 0.01 3.03% |
Biotechnology Assets seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Biotechnology Assets from analyzing the firm fundamentals such as Profit Margin of (0.92) %, shares outstanding of 48.35 M, and Return On Equity of -0.74 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Biotechnology Assets' price fluctuation is out of control at this time. Calculation of the real value of Biotechnology Assets is based on 3 months time horizon. Increasing Biotechnology Assets' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biotechnology Assets is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biotechnology Stock. However, Biotechnology Assets' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.34 | Real 0.27 | Hype 0.34 | Naive 0.36 |
The real value of Biotechnology Stock, also known as its intrinsic value, is the underlying worth of Biotechnology Assets Company, which is reflected in its stock price. It is based on Biotechnology Assets' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biotechnology Assets' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biotechnology Assets SA helps investors to forecast how Biotechnology stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotechnology Assets more accurately as focusing exclusively on Biotechnology Assets' fundamentals will not take into account other important factors: Biotechnology Assets Total Value Analysis
Biotechnology Assets SA is currently anticipated to have takeover price of 0 with market capitalization of 13.64 M, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Biotechnology Assets fundamentals before making investing decisions based on enterprise value of the companyBiotechnology Assets Asset Utilization
One of the ways to look at asset utilization of Biotechnology is to check how much profit was generated for every dollar of assets it reports. Biotechnology Assets SA shows a negative utilization of assets of -0.0647 percent, losing USD6.47E-4 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Biotechnology Assets SA shows how discouraging it operates for each dollar spent on its assets.Biotechnology Assets Ownership Allocation
Biotechnology Assets holds a total of 48.35 Million outstanding shares. Biotechnology Assets SA retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biotechnology Assets' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biotechnology Assets and how it compares across the competition.
About Biotechnology Assets Valuation
The stock valuation mechanism determines Biotechnology Assets' current worth on a weekly basis. Our valuation model uses a comparative analysis of Biotechnology Assets. We calculate exposure to Biotechnology Assets's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biotechnology Assets's related companies.8 Steps to conduct Biotechnology Assets' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Biotechnology Assets' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Biotechnology Assets' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Biotechnology Assets' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Biotechnology Assets' revenue streams: Identify Biotechnology Assets' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Biotechnology Assets' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Biotechnology Assets' growth potential: Evaluate Biotechnology Assets' management, business model, and growth potential.
- Determine Biotechnology Assets' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Biotechnology Assets' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Biotechnology Stock analysis
When running Biotechnology Assets' price analysis, check to measure Biotechnology Assets' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotechnology Assets is operating at the current time. Most of Biotechnology Assets' value examination focuses on studying past and present price action to predict the probability of Biotechnology Assets' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotechnology Assets' price. Additionally, you may evaluate how the addition of Biotechnology Assets to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |